Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study

Blood

Volumn 105, Issue 7, 2005, Pages 2664-2670

  Finazzi, Guido ^b   Caruso, Vanesa ^b   Marchioli, Roberto ^a   Capnist, Giovanni ^b   Chisesi, Teodoro ^b   Finelli, Carlo ^b   Gugliotta, Luigi ^b   Landolfi, Raffaele ^b   Kutti, Jack ^b   Gisslinger, Heinz ^b   Marilus, Raphael ^b   Patrono, Carlo ^b   Pogliani, Enrico Maria ^b   Randi, Maria Luigia ^b   Villegas, Ana ^b   Tognoni, Gianni ^b   Barbui, Tiziano ^b  

^a Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; INTERFERON; PHOSPHORUS 32; PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; LEUKEMOGENESIS; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTOSIS;

EID: 20144389274     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3426     Document Type: Article

References (39)

1. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-447.
2. Haanen C, Mathe G, Hayat M. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized clinical trial. Br J Cancer. 1981;44:75-80.
3. Najean Y, Rain J-D. A very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997;34:6-16.
4. Najean Y, Rain J-D for the French Polycythemia Study Group. Treatment of polycythemia vera: use of P32 alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood. 1997;89:2319-2327.
5. Najean Y, Rain JD for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
6. Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Haematol. 1984;17:329-334.
7. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34:17-23.
8. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52:134-139.
9. Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol. 1997;34:24-28.
10. Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol. 1984;2:558-561.
11. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000;85:1011-1018.
12. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J. 2003;4:198-207.
13. Nand S, Messmore H, Fisher SG, et al. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990;34:32-36.
14. Najean Y, Deschamps A, Dresch C, et al. Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow-up. Cancer. 1988;61:89-95.
15. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc. 1991;66:287-299.
16. Landaw SA. Acute leukemia in polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA: WB Saunders; 1995: 154-165.
17. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood. 1988;72:386-395.
18. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
19. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132-143.
20. Pearson TC, Messinezy M. The diagnostic criteria of polycythemia rubra vera. Leuk Lymphoma. 1996;22(suppl 1):87-93.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) Cooperative Group. Br J Haematol. 1976;33:451-458.
22. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
23. Ghali WA, Quan H, van Melle G, et al. JAMA. 2001;286:1494-1497
24. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13-18.
25. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
26. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000;79:312-318.
27. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74:26-31.
28. Halnan KE, Russell MH. Polycythemia vera: comparison of survival and causes of death in patients managed with and without radiotherapy. Lancet. 1965;2:760-763.
29. Linet MS, Devesa SS. Epidemiology of leukemia: overview and patterns of occurrence. In: Henderson ES, Lister TA, Greaves M, eds. Leukemia. 7th ed. Philadelphia, PA: WB Saunders; 2002: 131-151.
30. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233-235.
31. Pearson TC, Green AR, Reilly JT, Harrison G. Leukemic transformation in polycythemia vera. Blood. 1998;92:1837-1842.
32. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med. 1995;332:1132-1136.
33. Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.
34. Marini A, Carulli G, Azzara A, Grassi B, Ambrogi F. Serum cholesterol and triglycerides in hematological malignancies. Acta Haematol. 1989;81:75-79.
35. Pandolfino J, Hakimian D, Rademaker AW, Tallman MS. Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity. Am J Hematol. 1997;55:129-133.
36. Gilbert HS, Ginsberg H, Fagerstrom R, Brown WV. Characterization of hypocholesterolemia in myeloproliferative disease: relation to disease manifestations and activity. Am J Med. 1981;71:595-602.
37. Aixala M, Sarandria CN, Speroni JG. Hypocholesterolemia in hematologic neoplasms. Sangre (Barc). 1997;42:7-10.
38. The Italian Cardiovascular Epidemiological Observatory. Ital Heart J. 2004;5(suppl 3):49S-92S.
39. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 1987;257:943-948.